Merck & Co. reported positive results from two Phase III trials of their oral PCSK9 inhibitor enlicitide decanoate, achieving statistically significant reductions in LDL cholesterol in patients with hyperlipidemia. This oral therapy aims to compete within the crowded PCSK9 market dominated by injectable drugs, potentially enhancing patient adherence. The trials affirm Merck’s progress towards regulatory submission and market entry for what may be the first oral PCSK9 inhibitor treatment.